A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations

Phase 4

Completed

• Conditions: Non-Squamous Non-Small Cell Lung Cancer
• Interventions: Drug: erlotinib [Tarceva]

• Registration Number: NCT01609543
• Lead Sponsor: Hoffmann-La Roche

Brief Summary

This open-label, non-randomized, one-arm study will evaluate the safety and efficacy of Tarceva (erlotinib) as single-agent first-line treatment in patients with locally advanced or metastatic non-small cell lung cancer who show epidermal growth factor receptor (EGFR) activating mutations. Patients will receive Tarceva 150 mg orally daily until disease progression or unacceptable toxicity occurs.

Detailed Description

Not available

Study Timeline

• Study Start: 2012-05
• Study First Submitted: 2012-05-30
• Study First Submitted QC: 2012-05-30
• Study First Posted: 2012-06-01
• Primary Completion: 2015-01
• Study Completion: 2015-01
• Status Verified: 2015-12
• Results First Submitted: 2015-12-29
• Results First Submitted QC: 2015-12-29
• Last Update Submitted: 2015-12-29
• Results First Posted: 2016-02-01
• Last Update Posted: 2016-02-01

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 62

Inclusion Criteria

• Adult patients, >/= 18 years of age
• Histologically or cytologically documented, inoperable, locally advanced, recurrent or metastatic (Stage IIIB or Stage IV) lung adenocarcinoma
• Non-small cell lung cancer with an EGFR activating mutation
• Patients must have evidence of disease, but measurable disease is not mandatory
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Adequate renal and liver function

Read More

Exclusion Criteria

• Prior chemotherapy or other systemic anti-cancer treatment. Neoadjuvant/adjuvant chemotherapy is allowed if completed within 6 months prior to enrolment. Prior radiochemotherapy is allowed if completed more than 6 months before start of study treatment
• Prior therapy with systemic anti-tumour therapy with HER1/EGFR inhibitors
• Any other malignancies within 5 years, except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin carcinoma
• Brain metastasis or spinal cord compression not yet definitely treated with surgery and/or radiation
• Patients unable to take oral medication or requiring intravenous alimentation, with prior surgical procedures affecting absorption or active peptic ulcer disease
• Any significant ophthalmologic abnormality, especially those likely to increase the risk of corneal epithelial lesions; the use of contact lenses is not recommended during the study
• Pregnant or breast-feeding women

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single Arm	erlotinib [Tarceva]	-

Primary Outcome Measures

Name	Time	Method
Progression-Free Survival (PFS)	Baseline to progressive disease or death (up to 34 months)	PFS was defined as median time from the first dose of study treatment to the first documentation of objective tumor progression (according to Response Evaluation Criteria in Solid Tumours \[RECIST\] version 1.1) or to death due to any cause, whichever occurred first. Progressive Disease (PD) was defined as at least a 20 percent (%) increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression. Median and the 95% confidence interval were estimated using Kaplan-Meier survival methodology.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants With Best Overall Response (BOR)	Baseline to progressive disease or death (up to 34 months)	BOR was defined as best tumor response (as per RECIST version 1.1) recorded for a participant during the study. Complete Response (CR): disappearance of all target and non-target lesions and normalization of tumor marker level. All lymph nodes must be non-pathological in size (less than \[\<\] 10 millimeters \[mm\] short axis). Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. PD: at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. Unequivocal progression of existing non-target lesions. The appearance of one or more new lesions is also considered progression. Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Percentage of Participants Who Were Alive at 1 Year	1 Year (12 months)